|Assessing impact of COVID19 Wiki
|Vacciantion status in health care workers Wiki
|MCC IMS Wiki
|Thoraxic computed tomography Wiki
|IL-12 plasmid Wiki
|Respiratory infections Wiki
|Prophylactic/Intermediate Dose Enoxaparin Wiki
|qRT-PCR and serology Wiki
|Video about safety and effectiveness of adult seasonal flu vaccination Wiki
|Message directing subjects to information on COVID-19 vaccine safety and efficacy Wiki
|Scanning Chest X-rays and performing AI algorithms on images Wiki
|Lung CT Wiki
|ACE inhibitor Wiki
|Blood sample Wiki
|Convalescent Plasma Wiki
|Bacterial Infections NIH
|RNA Virus Infections NIH
|Respiratory Tract Infections NIH
|Pneumonia, Ventilator-Associated NIH
|Lung Diseases, Interstitial NIH
|Communicable Diseases NIH
|Disease Progression NIH
|Lung Injury NIH
|Pneumonia, Viral NIH
|Virus Diseases NIH
|Acute Lung Injury NIH
|Severe Acute Respiratory Syndrome NIH
|Coronavirus Infections NIH
There are 11 clinical trials
The aim of the study is to identify what sender/signal combinations are most persuasive in encouraging low socioeconomic males living in the U.S. to take-up seasonal flu vaccination. The investigators plan to recruit male subjects and randomly assign them to four persuasion treatments: three of which vary dimensions of the sender of a medical recommendation (racial concordance, gender concordance, and authority treatments) and one which varies the signal (standard vs. empathetic). Specifically, the investigators will show subjects videos of either Black or white actors/actresses providing scripted information on the flu vaccination. The investigators will randomize the race of the sender and if the subject is Black, also randomize the authority of the sender, with the actor portraying either a doctor or a layperson. Conditional on project funding, subjects assigned to a concordant sender will have the gender of the sender randomized. In addition, the investigators will vary the script used in the experiment between one that acknowledges past injustices (indicated as an empathetic script hereafter) and one that does not (indicated as a standard script hereafter). The investigators will provide subjects a free flu shot coupon and elicit the price at which subjects would be willing to give up this coupon for a cash reward. Lastly, in light of the relevance of vaccination take-up in combating COVID-19 pandemic, the investigators will assess demand for information about a COVID-19 vaccine, with subjects invited to receive results of a safety and efficacy review from a trusted or standard source. The design requires collection of baseline and endline surveys combined with administrative data from pharmacies about coupon redemption. The primary outcomes of interest are posterior beliefs about seasonal flu vaccination, demand and willingness-to-pay (WTP) for a free flu shot coupon, redemption of the coupon, and demand for information about a COVID-19 vaccine.
Description: The investigators will examine whether a subject updated their beliefs about the risk and benefits of the flu shot after watching the infomercial video.Measure: Posterior beliefs about the risk/benefits of the flu shot Time: This outcome will be assessed during Baseline survey, which takes approximately 20 minutes.
Description: The investigators will examine whether subjects invited to receive information on COVID-19 vaccine safety and efficacy from a concordant source exhibited higher demand for such information.Measure: Demand for information about a COVID-19 vaccine Time: This outcome will be assessed during Baseline survey, which takes approximately 20 minutes.
Description: The investigators will elicit and measure a subject's flu shot coupon valuations.Measure: Willingness-to-pay (WTP) for a free flu shot coupon Time: This outcome will be assessed during Baseline survey, which takes approximately 20 minutes.
Description: The investigators will measure a subject's level of attention and recall from the infomercial video, which could potentially affect their belief updating and decisions on coupon redemption.Measure: Level of attention and recall from the infomercial video during Baseline survey Time: This outcome will be assessed during Baseline survey, which takes approximately 20 minutes.
Description: The investigators will measure a subject's level of attention and recall from the infomercial video, which could potentially affect their belief updating and decisions on coupon redemption.Measure: Level of attention and recall from the infomercial video during Endline survey Time: This outcome will be assessed during Endline survey, which takes approximately 2 weeks to 3 months after the intervention (depending on the characteristics of the flu season).
Description: The investigators will collect information indicating whether a subject redeemed a flu shot coupon after watching the infomercial video.Measure: Redemption of said coupon Time: This outcome will be assessed during the time between Baseline and Endline survey (approximately 2 weeks to 3 months time gap, depending on the characteristics of the flu season).
Multicapillary Ion mobility spectrometry of nasal air aspirates shall be investigated as screening tool for the detection of Influenza and SARS-CoV-2- infection.
Description: Cluster Analysis of MCC IMS spectra will be obtained immediately after samplingMeasure: Cluster Analysis of MCC IMS spectra. Time: immediatly after sampling
This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.
Description: Percent of subjects who have returned to room airMeasure: Percent of subjects who have returned to room air Time: 7 days
Description: Percent change of subjects return to baseline oxygen requirement by Day 7 compared to Day 1Measure: Percent change of subjects return to baseline oxygen requirement Time: 7 days
This project aims to use artificial intelligence (image discrimination) algorithms, specifically convolutional neural networks (CNNs) for scanning chest radiographs in the emergency department (triage) in patients with suspected respiratory symptoms (fever, cough, myalgia) of coronavirus infection COVID 19. The objective is to create and validate a software solution that discriminates on the basis of the chest x-ray between Covid-19 pneumonitis and influenza
Description: Number of participants with pneumonitis on Chest X-Ray and COVID 19 positiveMeasure: COVID-19 positive X-Rays Time: 6 months
Description: Number of participants with pneumonitis on Chest X-Ray and COVID 19 negativeMeasure: COVID-19 negative X-Rays Time: 6 months
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving treatment show a better evolution.
Description: exitus vs hospital outputMeasure: hospital output Time: from March 1, 2020.
Description: lenght of the hospital stayMeasure: hospital stay Time: From March 1, 2020.
The investigators decided to conduct a longitudinal study that compares the pulmonary tomographic patterns found in patients with viral pneumonia (i.e. influenza H1N1 and SARS-CoV-2) at a regional hospital. The primary aim of this study is to compare the radiological patterns found in patients with COVID-19 and influenza H1N1. The secondary aims of this study will assess the association between the radiological CT pattern and the need for invasive mechanical ventilation and mortality within the first 28 days of intensive care unit admission.
Description: Lung CT radiological patterns associated with COVID-19 or Influenza H1N1Measure: Radiological findings Time: 24 hours
Description: Intrahospital and overall survival at 28 days from hospital admission.Measure: Survival Time: 28 days
The investigators decided to conduct a longitudinal study that compares the pulmonary tomographic patterns found in patients with viral pneumonia (i.e. influenza H1N1 and SARS-CoV-2) at a regional hospital. The primary aim of this study is to evaluate the association between the radiological CT pattern and the need for invasive mechanical ventilation. A secondary aim is to assess the mortality within the first 28 days of intensive care unit admission.
Description: Need for oral intubation within the first 10 days.Measure: Oral intubation Time: 10 days
Description: 28-day survival analysis using the Kaplan Meyer and Cox regression models.Measure: Survival Time: 28 days
Background: Each Belgian winter season is characterized by a wave of influenza like and respiratory symptoms. Especially, the elderly people are more vulnerable to be infected by influenza, but also RSV. The recent COVID-19 pandemic and eventually a next wave, will increase the prevalence of influenza like and respiratory symptoms. Method: A multicentre non-commercial cohort study will be conducted in nursing home staff and residents during the Winter season 2020-2021. Objectives: Primary objective is the difference in incidence of influenza like and respiratory symptoms between cases (cases have evidence of past infection with SARS-CoV-2, referred to as Covid +) and controls (controls have no evidence of previous infection and are referred to as Covid -). The primary outcome analysis as well as the secondary outcome analyses will use two strata: nursing home staff and nursing home residents. The secondary objectives are the difference in incidence of COVID-19, influenza, RSV infections confirmed by PCR between cases and controls, to define a correlate of protection in the covid + group against re-infection with SARS-CoV-2 based on the study of the pre-existing antibody profile (antigen specificity, antibody type and antibody level) at the time of re-exposure. A multiplex assay will be used to assess the antibody profile. Finally, to study the COVID-19 disease severity (7 point WHO ordinal scale, this includes a.o. hospitalisation, mechanical ventilation need and ICU admission, mortality) based on the presence/absence of pre-existing antibodies and the pre-existing antibody profile. For other respiratory infections we will study the need for hospitalization and mortality.
Description: This study will assess the time to the occurrence of influenza-like illness (ILI) or acute respiratory infection (ARI) in subjects previously COVID+ compared to subjects known as COVID- (controls), more specifically subjects will belong to two subgroups: nursing home residents (65+) and nursing home staff (18-65y). COVID+ is defined as a past SARS-CoV-2 infection.Measure: Time to occurrence of ILI and ARI both in participants previously exposed to SARS-COV-2 and controls Time: up to 8 months
Description: Disease severity will be measured by hospitalization and mortalityMeasure: Correlation of the pre-existing antibody characteristics for COVID-19 with disease severity. Time: up to 8 months
The proposed study is designed to investigate if and how pregnant women infected with Coronavirus Disease-19 (COVID-19) infection go on to develop long-term immunity. In December 2019, a group of people in Wuhan, China presented with symptoms of a pneumonia of an unknown cause that led to the discovery of a new coronavirus called COVID-19. COVID-19 has caused a global pandemic with 7,140,000 confirmed cases and 418,000 deaths as of 13th June 2020. In the United Kingdom (UK), there have been 294,000 cases and 41,662 deaths as of 13th June 2020. In humans, this infection primarily involves the upper part of the lungs, but it can also affect other organs. It causes mild symptoms in the majority of people affected but some people can have severe infections, with some even requiring critical care in hospital. During Severe acute respiratory syndrome (SARS), a previous coronavirus epidemic, pregnant women were disproportionately affected with severe illness. Understanding how the immune system responds long-term to this infection may hold the key to developing better vaccines and efficient treatment plans. Specialised immunity develops when individuals are infected by this and other viruses. The investigators of this study propose that, in pregnancy, this specialised immunity may not behave effectively. This may affect their ability to develop long lasting immunity and make them more vulnerable to re-infection. In this study, the investigators aim to recruit patients across 6 groups including COVID-19 newly infected pregnant women, and people with differing illness severity, mild to moderate, severe/critical, no infection (controls), as well as pregnant women with influenza and those receiving influenza vaccine. The study team will compare COVID-19 in pregnancy with non-pregnant infected and with influenza infected and vaccinated pregnant women. The study team will consent patients in all of these groups to provide a series of blood samples at different time points in a 12-month period.
Description: Devise a flow cytometry panel to phenotype B cells.Measure: Phenotyping antibody secreting cells (ASCs) and memory B cells during COVID-19 infection, and post recovery. Time: Groups A, B, D: Between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months) post infection. Group C: 1 day. 1 time point.
Description: B cell ELISpot assay and quantify Immunoglobulin A (IgA) and IgG using Enzyme-linked immunosorbent assay (ELISA) from plasma and/or serum from COVID-19 recovered individuals.Measure: Quantification of SARS-CoV-2 specific IgG production by memory B cells to measure long-lasting immune protection against re-infection. Time: Groups A, B, D: Between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months) post infection. Group C: 1 day. 1 time point.
Description: Use real-time PCR (RT-PCR) and nested PCR to detect SARS-CoV-2 viral loadMeasure: Quantification of SARS-COV-2 viral load using PCR. Time: Groups A, B, D: at 7-14 days and during recovery phase. Group C: 1 day. 1 time point.
Description: Devise a flow cytometry panel to phenotype cTFH cells.Measure: Immuno-phenotype circulatory T follicular helper cells (cTFH) cells post SARS-CoV-2 infection. Time: Groups A, B, D: at 7-14 days post infection or vaccination. Group C: 1 day. 1 time point.
Description: Use a combination of flow cytometry, enzyme-linked immunospot (ELISpot) assays, and DNA/RNA analysis.Measure: Investigating T cell mediated immune function post COVID-19 Time: Groups A, B, D: Between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months) post infection/vaccination. Group C: 1 day. 1 time point.
Description: Parameters including antibody titres, cTFH and memory B cell and ASC proportions, and T cell function will be compared between COVID-19 infected, and influenza infected and vaccinated pregnant women.Measure: In pregnancy, comparing antibody production, and immune phenotype and function (as outlined above) between COVID-19 infection, and influenza infected or vaccinated. Time: Groups A, B, D, E and F: Between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months) post infection/vaccination. Group C: 1 day. 1 time point.
The study will be conducted in the UCKWUM teaching hospital in Warsaw between 2020 and 2022. The study group will be comprised of UCKWUM healthcare professionals All employees willing to participate in the study will receive an anonymous questionnaire on attitudes towards influenza vaccination . We will distribute information posters of the National Programme for Combating Influenza as part of the educational programme. In order to increase the effectiveness of the educational campaign, we will also send information e-mails, using the internal hospital e-mail system and conduct a series of online training courses to present the latest international reports on influenza vaccinations among health care professionals [CITATION Abr10 \l 1045]. Considering the fact that lack of time [CITATION Kus11 \l 1045] is the most common reason for not getting vaccinated against influenza among healthcare professionals, we will provide this group with an opportunity to receive free influenza vaccination during working hours at the UCKWUM hospital. Information about the possibility of vaccination will be provided in the form of e-mails (mailings) to hospital employees (internal hospital e-mail system), letters of information submitted to the offices of individual departments, and information posters. The effectiveness of the educational programme will be assessed by re-administering the anonymous questionnaires after the influenza season, also by means of internal hospital e-mail system.
Respiratory infections such as colds, flu and pneumonia affect millions of people around the world every year. Most cases are mild, but some people become very unwell. Influenza ('flu') is one of the most common causes of lung infection. Seasonal flu affects between 10% and 46% of the population each year and causes around 12 deaths in every 100,000 people infected. In addition, both influenza and coronaviruses have caused pandemics in recent years, leading to severe disease in many people. Although flu vaccines are available, these need to change every year to overcome rapid changes in the virus and are not completely protective. This study aims to find and develop predictive tests to better understand how and when flu-like illness progresses to more severe disease. This may help to decide which people need to be admitted to hospital, and how their treatment needs to be increased or decreased during infection. The aim is to recruit 100 patients admitted to hospital due to a respiratory infection. It is voluntary to take part and participants can choose to withdraw at any time. The study will involve some blood and nose samples. This will be done on Day 0, Day 2 and Discharge from hospital, and an out-patient follow-up visit on Day 28. The data will be used to develop novel diagnostic tools to assist in rational treatment decisions that will benefit both individual patients and resource allocation. It will also establish research preparedness for upcoming pandemics.
Description: The identity of pathological organisms associated with influenza-like illness (including respiratory viruses and bacteria) will be obtained from the patient's medical recordMeasure: Describe the aetiology of influenza-like illness in hospitalised adults Time: Day 0 to Day 28
Description: The following data will be collected from the patient's medical record. At enrolment, data will consist of: past medical history, clinical signs and symptoms relating to this admission, vital signs (pulse rate, blood pressure, temperature, oxygen saturation), demographics, drug history, laboratory results including diagnostic microbiological tests and interventions. Data collection on Day 28 will consist of clinical diagnosis at discharge, any febrile illness in the 7 days preceding the visit, mortality and complications between Day 0 and 28.Measure: Describe the clinical outcomes of influenza-like illness in hospitalised adults Time: Day 0 to Day 28
Description: Cytokine levels (in pg/mL) will be measured in plasma and nasal lining fluid samples by MesoScale DiscoveryMeasure: Identify changes in cytokine levels during influenza-like illness in hospitalised adults Time: Day 0 to Day 28
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports